Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
暂无分享,去创建一个
C. Punt | J. Picus | L. Terstappen | M. Morse | G. Doyle | M. Miller | N. Meropol | N. Iannotti | B. Saidman | K. Sabbath | N. Gabrail | E. Mitchell | H. Tissing | M C Miller | L W M M Terstappen | C J A Punt | H Tissing | S. Cohen | K D Sabbath | S J Cohen | G V Doyle | N Iannotti | B H Saidman | N Y Gabrail | J Picus | M A Morse | E Mitchell | N J Meropol | Neal J. Meropol | Steven J. Cohen | M. Miller | M. Miller
[1] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[3] A Messori,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[4] L. Weiner,et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. , 2006, Clinical colorectal cancer.
[5] C. Denlinger,et al. Progress in the Development of Prognostic and Predictive Markers for Gastrointestinal Malignancies , 2007, Current treatment options in oncology.
[6] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Daniel F Hayes,et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[10] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[11] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[12] D. Sargent,et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Leon W M M Terstappen,et al. Statistical considerations for enumeration of circulating tumor cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.